Addressing the Growing Need for Medications for Children

Pediatric development plans are a requirement for all new medicines, indications, dosing forms, regimens, and routes of administration, and pediatric clinical research is on the rise. Additionally, all applications for marketing authorization for new medicines must include the results of studies in children as described in an agreed-upon pediatric plan, unless the medicine is exempt because of a deferral or waiver.

Understanding the Diversity of Pediatric Clinical Trials

At Synteract, we are at the forefront of working with sponsors in pediatric drug development with broad experience across 6 continents in over 62 countries.

Conducting Pediatric Clinical Trials with Heart

Pediatric drug development requires special care in recruitment to address ethical, scientific, and logistical challenges. We understand the compassionate, specialized clinical and regulatory expertise required when working with vulnerable pediatric populations and their families. We have experience working with international pediatric networks, opinion leaders, patient advocacy groups, and regulatory bodies, with many of our executives actively involved in the industry, and can capitalize on relationships with global partners invested in this patient population.

We can assist with all aspects of pediatric drug development, including medical and regulatory strategy; trial design; creation, submission, follow-up and updates of PSPs and PIPs, and more. Our clinical experts will guide you through evolving global regulations and data requirements each step of the way.

A - Respiratory: 16%
B - Endocrinology: 14%
C - Gastroenterology: 10%
D - Infectious Disease: 10%
E - Hematology: 9%
F - Dermatology: 7%
G - Metabolic: 7%
H - Dental: 5%
I - Neurology: 4%
J - Nutrition: 3%
K - Oncology: 3%
L - Cardiology: 2%
M - Ophthalmology: 2%
N - Psychiatry: 1%
O - Cosmetic: 1%

We have performed, in the last 5 years: 140+ PROJECTS  65+ INDICATIONS
About Synteract:

Synteract is an innovative, full-service CRO supporting biopharma companies across all phases of drug development to help bring new medicines to market. Synteract has conducted 4,000 studies on six continents and in more than 60 countries, working with more than 26,000 investigative sites and 750,000 patients. It has contributed to more than 240 product approvals. Synteract offers a notable depth of expertise in oncology, general medicine, dermatology, and neuroscience indications, as well as rare and orphan, pediatric, and immunotherapy studies.

For more information on how we can support your clinical trial, please visit www.synteract.com/Therapeutic-Expertise/Pediatrics or ContactUs@synteract.com.